Yazhe Wang

Yazhe Wang

Auto-generated profile, based on publicly available information

Yazhe Wang

Department of Biomedical Engineering, Yale University, New Haven, Connecticut. 4

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2023 in Science Advances
Verified
Journal Article
Closed access
YWYazhe Wang
Yazhe Wang
SMShipra Malik
Shipra Malik
HSHee-Won Suh
Hee-Won Suh
YXYong Xiao
Yong Xiao
YDYanxiang Deng
Yanxiang Deng
RBRaman Bahal
Raman Bahal
Glioblastoma (GBM) is one of the most lethal malignancies with poor survival and high recurrence rates. Here, we aimed to simultaneously target oncomiRs 10b and 21, reported to drive GBM progression and invasiveness. We designed short (8-mer) γ-modified peptide nucleic acids (sγPNAs), targeting the seed region of oncomiRs 10b and 21. We entrapped these anti-miR sγPNAs in nanoparticles (NPs) formed from a block copolymer of poly(lactic acid) and hyperbranched polyglycerol (PLA-HPG). The surface of the NPs was functionalized with aldehydes to produce bioadhesive NPs (BNPs) with superior transfection efficiency and tropism for tumor cells. When combined with temozolomide, sγPNA BNPs administered via convection-enhanced delivery (CED) markedly increased the survival (>120 days) of two orthotopic (intracranial) mouse models of GBM. Hence, we established that BNPs loaded with anti-seed sγPNAs targeting multiple oncomiRs are a promising approach to improve the treatment of GBM, with a potential to personalize treatment based on tumor-specific oncomiRs.

1 May 2024 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
MMMatthew A. Murray
Matthew A. Murray
KNKatelyn J. Noronha
Katelyn J. Noronha
YWYazhe Wang
Yazhe Wang
AFAnna P. Friedman
Anna P. Friedman
SPSateja Paradkar
Sateja Paradkar
RBRanjit Bindra
Ranjit Bindra
The treatment of primary central nervous system tumors is challenging due to the blood–brain barrier and complex mutational profiles, which is associated with low survival rates. However, recent studies have identified common mutations in gliomas [isocitrate dehydrogenase (IDH)-wild-type and mutant, WHO grades II–IV; with grade IV tumors referred to as glioblastomas (GBM)]. These mutations drive epigenetic changes, leading to promoter methylation at the nicotinic acid phosphoribosyl transferase (NAPRT) gene locus, which encodes an enzyme involved in generating NAD+. Importantly, NAPRT silencing introduces a therapeutic vulnerability to inhibitors targeting another NAD+ biogenesis enzyme, nicotinamide phosphoribosyl transferase (NAMPT), rationalizing a treatment for these malignancies. Multiple systemically administered NAMPT inhibitors (NAMPTi) have been developed and tested in clinical trials, but dose-limiting toxicities—including bone marrow suppression and retinal toxicity—have limited their efficacy. Here, we report a novel approach for the treatment of NAPRT-silenced GBMs using nanoparticle (NP)-encapsulated NAMPTis administered by convection-enhanced delivery (CED). We demonstrate that GMX1778 (a NAMPTi) can be formulated in degradable polymer NPs with retention of potency for NAMPT inhibition and anticancer activity in vitro, plus sustained drug release in vitro and in vivo. Direct injection of these drugs via CED into the brain is associated with reduced retinal toxicity compared with systemic administration. Finally, we show that CED of NP-encapsulated GMX1778 to NAPRT-silenced intracranial GBM xenografts in mice exhibit significant tumor growth delay and extends survival. These data support an approach to treat gliomas harboring defects in NAD+ metabolism using CED of NP-encapsulated NAMPTis to greatly improve the therapeutic index and treatment efficacy for this class of drugs.

9 December 2023 in International Journal of Laboratory Hematology
Verified
Journal Article
Closed access
KSKai Sun
Kai Sun
JWJun Wang
Jun Wang
YWYa‐Zhe Wang
Ya‐Zhe Wang
ZSZong‐Yan Shi
Zong‐Yan Shi
YCYan Chang
Yan Chang
YQYa-Zhen Qin
Ya-Zhen Qin

1 December 2013
Verified
Journal Article
Closed access
YWYa-Zhe Wang
Ya-Zhe Wang
YCYan Chang
Yan Chang
DLDan Lu
Dan Lu
HSHong-Xia Shi
Hong-Xia Shi
Xiaojun HuangXiaojun Huang
Xiaojun Huang
Yanrong LiuYanrong Liu
Yanrong Liu

17 June 2026
Verified
Other
Open access
MMMatthew A. Murray
Matthew A. Murray
KNKatelyn J. Noronha
Katelyn J. Noronha
YWYazhe Wang
Yazhe Wang
AFAnna P. Friedman
Anna P. Friedman
SPSateja Paradkar
Sateja Paradkar
RBRanjit Bindra
Ranjit Bindra
Validation of PLA-PEG GMX1778 efficacy in an IDH1-R132H model.

17 June 2026
Verified
Other
Open access
PDF file
MMMatthew A. Murray
Matthew A. Murray
KNKatelyn J. Noronha
Katelyn J. Noronha
YWYazhe Wang
Yazhe Wang
AFAnna P. Friedman
Anna P. Friedman
SPSateja Paradkar
Sateja Paradkar
RBRanjit Bindra
Ranjit Bindra
Efficacy of BNP GMX1778 in PPM1Dtrnc. isogenic model.